Cargando…

Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus

OBJECTIVE: To determine the toxicity and efficacy of radiotherapy for cervical cancer in patients with systemic lupus erythematosus (SLE). METHODS: Medical records of patients with SLE who received radiation for cervical cancer from January 2011 to January 2019 were reviewed. For definitive radiothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jiabin, Wang, Weiping, Shen, Jing, Hou, Xiaorong, Lian, Xin, Yan, Junfang, Sun, Shuai, Miao, Zheng, Meng, Qingyu, Hu, Ke, Zhang, Fuquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518778/
https://www.ncbi.nlm.nih.gov/pubmed/33061566
http://dx.doi.org/10.2147/CMAR.S264795
_version_ 1783587450802667520
author Ma, Jiabin
Wang, Weiping
Shen, Jing
Hou, Xiaorong
Lian, Xin
Yan, Junfang
Sun, Shuai
Miao, Zheng
Meng, Qingyu
Hu, Ke
Zhang, Fuquan
author_facet Ma, Jiabin
Wang, Weiping
Shen, Jing
Hou, Xiaorong
Lian, Xin
Yan, Junfang
Sun, Shuai
Miao, Zheng
Meng, Qingyu
Hu, Ke
Zhang, Fuquan
author_sort Ma, Jiabin
collection PubMed
description OBJECTIVE: To determine the toxicity and efficacy of radiotherapy for cervical cancer in patients with systemic lupus erythematosus (SLE). METHODS: Medical records of patients with SLE who received radiation for cervical cancer from January 2011 to January 2019 were reviewed. For definitive radiotherapy, a dose of 50.4 Gy in 28 fractions was delivered by intensity-modulated radiation therapy (IMRT) combined with high-dose-rate brachytherapy of 28 to 30 Gy in 5 fractions. A dose of 45 to 50.4 Gy in 25–28 fractions was delivered for postoperative radiation. All patients were in remission with or without a low dosage of prednisone or immunosuppressive medication. Survival data were analyzed with the Kaplan–Meier method. The incidence of severe toxicities among patients was compared with the chi-square test or Fisher’s exact test. RESULTS: Twelve patients with SLE were included in this study. Definitive radiotherapy was delivered in 7 patients with FIGO (2009) stage II–III disease. Five patients with FIGO I disease received postoperative radiation. The median follow-up time was 22.1 months. The 3-year overall survival (OS) and 3-year progression-free survival (PFS) were 77.8% and 83.3%, respectively. One patient of definitive radiotherapy and one patient of postoperative radiation died due to distant metastasis of cervical cancer. Grade 3 or higher acute and chronic reactions occurred in 58.3% and 8.3% patients, respectively. Acute grade 3 or higher toxicity correlated with the presence of chemotherapy (p = 0.045). CONCLUSION: Modern radiotherapy for cervical cancer was well tolerated in SLE patients with remission and provided a favorable outcome.
format Online
Article
Text
id pubmed-7518778
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75187782020-10-14 Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus Ma, Jiabin Wang, Weiping Shen, Jing Hou, Xiaorong Lian, Xin Yan, Junfang Sun, Shuai Miao, Zheng Meng, Qingyu Hu, Ke Zhang, Fuquan Cancer Manag Res Original Research OBJECTIVE: To determine the toxicity and efficacy of radiotherapy for cervical cancer in patients with systemic lupus erythematosus (SLE). METHODS: Medical records of patients with SLE who received radiation for cervical cancer from January 2011 to January 2019 were reviewed. For definitive radiotherapy, a dose of 50.4 Gy in 28 fractions was delivered by intensity-modulated radiation therapy (IMRT) combined with high-dose-rate brachytherapy of 28 to 30 Gy in 5 fractions. A dose of 45 to 50.4 Gy in 25–28 fractions was delivered for postoperative radiation. All patients were in remission with or without a low dosage of prednisone or immunosuppressive medication. Survival data were analyzed with the Kaplan–Meier method. The incidence of severe toxicities among patients was compared with the chi-square test or Fisher’s exact test. RESULTS: Twelve patients with SLE were included in this study. Definitive radiotherapy was delivered in 7 patients with FIGO (2009) stage II–III disease. Five patients with FIGO I disease received postoperative radiation. The median follow-up time was 22.1 months. The 3-year overall survival (OS) and 3-year progression-free survival (PFS) were 77.8% and 83.3%, respectively. One patient of definitive radiotherapy and one patient of postoperative radiation died due to distant metastasis of cervical cancer. Grade 3 or higher acute and chronic reactions occurred in 58.3% and 8.3% patients, respectively. Acute grade 3 or higher toxicity correlated with the presence of chemotherapy (p = 0.045). CONCLUSION: Modern radiotherapy for cervical cancer was well tolerated in SLE patients with remission and provided a favorable outcome. Dove 2020-09-21 /pmc/articles/PMC7518778/ /pubmed/33061566 http://dx.doi.org/10.2147/CMAR.S264795 Text en © 2020 Ma et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ma, Jiabin
Wang, Weiping
Shen, Jing
Hou, Xiaorong
Lian, Xin
Yan, Junfang
Sun, Shuai
Miao, Zheng
Meng, Qingyu
Hu, Ke
Zhang, Fuquan
Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title_full Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title_fullStr Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title_full_unstemmed Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title_short Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus
title_sort radiotherapy for cervical cancer in patients with systemic lupus erythematosus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518778/
https://www.ncbi.nlm.nih.gov/pubmed/33061566
http://dx.doi.org/10.2147/CMAR.S264795
work_keys_str_mv AT majiabin radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT wangweiping radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT shenjing radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT houxiaorong radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT lianxin radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT yanjunfang radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT sunshuai radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT miaozheng radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT mengqingyu radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT huke radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus
AT zhangfuquan radiotherapyforcervicalcancerinpatientswithsystemiclupuserythematosus